<DOC>
	<DOCNO>NCT00311857</DOCNO>
	<brief_summary>GERT one-armed single-center phase I/II trial . In first step , dose-escalation TMZ 50 mg/m2 75mg/m2 together radiotherapy cetuximab perform . Should safety proven , phase II trial initiate standard dose 75mg/m2 TMZ . Cetuximab apply standard application dose 400mg/m2 week 1 , thereafter dose 250mg/m2 weekly . A total 46 patient include phase I/II trial . Primary endpoint feasibility toxicity , secondary endpoint overall progression-free survival . An interim analysis perform inclusion 15 patient main study . Patients ’ enrolment perform period 2 year . The observation time end 2 year inclusion last patient .</brief_summary>
	<brief_title>Safety Study Cetuximab , Radiotherapy Temozolomide Primary Glioblastoma Multiforme ( GERT )</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>&gt; = 18 &lt; 70 year age Karnofsky Performance Score &gt; = 60 histologically confirm supratentorial GBM interval primary diagnosis registration study &lt; 4 week patient include accord incidental gender distribution patient GBM ♀/♂ 2:3 adequate blood value ( old 14 day prior initiation RCHT ) neutrophil count ( ANC ) ≥1500/mm3 white blood cell ( WBC ) ≥2000/mm3 platelet ≥100.000/mm3 hemoglobin ≥10g/dL BUN &lt; 1.5 time upper range Total direct bilirubin &lt; 1.5times upper laboratory limit Adequate liver enzymes &lt; 3 time upper laboratory limit Life expectancy &gt; 12 week Written inform consent refusal patient take part study previous radiotherapy brain chemotherapy DTIC TMZ know allergy extrinsical protein previous chemotherapy therapy EGFRinhibitor Previous antibody therapy Patients yet recover acute toxicity prior therapy Acute infection require systemic application antibiotic Frequent vomit medical condition prevent oral application TMZ Clinically active kidney liver cardiac disease Known carcinoma &lt; 5 year ago ( exclude Carcinoma situ cervix , basal cell carcinoma , squamous cell carcinoma skin ) HIV Pregnant lactate woman Participation another clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>Cetuximab</keyword>
</DOC>